Sign up to save your podcasts
Or
Share EHDS and Pharma: Impact on R&D and Unresolved Challenges
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
EHDS and Pharma: Impact on R&D and Unresolved Challenges
1 view Mar 19, 2026 In-person video interviewsThe European Health Data Space (EHDS) isn't just a new regulation—it’s a "Magna Carta" for healthcare innovation. In this interview from the Smart Bridges Event, we sit down with industry expert Dennis Geisthardt, Head of digital.lab, to break down the implementation timeline (2025–2031) and what it means for the pharmaceutical industry, medtech, and patients across Europe.
We dive into the "Countdown to 2027," the challenges of intellectual property vs. data sharing, and how opening up access to clinical data could finally unlock breakthroughs for rare diseases and personalized medicine.
In this video, you’ll learn:
00:30 – Introduction: The Smart Bridges Event
03:45 – Why EHDS is a 100-year milestone for healthcare
04:30 – The role of the private sector in co-creating the framework
04:10 – What is EHDS? Primary vs. Secondary data use explained
05:00 – The Timeline: The "Countdown" to 2027, 2029, and 2031
06:30 – Who is a "Data Holder"? (Hospitals, Pharma, & MedTech)
07:45 – Industry Challenges: IP Rights, Trade Secrets, and Competition
08:50 – Revolutionizing Market Access (AMNOG) through data
09:40 – A "Magna Carta" for Rare Diseases and AI Research
10:30 – Identifying why therapies work (or fail) using broader datasets
11:20 – Closing: Why EHDS requires a "European Village" to succeed
View all episodes
By Tjasa Zajc
5
2020 ratings
1 view Mar 19, 2026 In-person video interviewsThe European Health Data Space (EHDS) isn't just a new regulation—it’s a "Magna Carta" for healthcare innovation. In this interview from the Smart Bridges Event, we sit down with industry expert Dennis Geisthardt, Head of digital.lab, to break down the implementation timeline (2025–2031) and what it means for the pharmaceutical industry, medtech, and patients across Europe.
We dive into the "Countdown to 2027," the challenges of intellectual property vs. data sharing, and how opening up access to clinical data could finally unlock breakthroughs for rare diseases and personalized medicine.
In this video, you’ll learn:
00:30 – Introduction: The Smart Bridges Event
03:45 – Why EHDS is a 100-year milestone for healthcare
04:30 – The role of the private sector in co-creating the framework
04:10 – What is EHDS? Primary vs. Secondary data use explained
05:00 – The Timeline: The "Countdown" to 2027, 2029, and 2031
06:30 – Who is a "Data Holder"? (Hospitals, Pharma, & MedTech)
07:45 – Industry Challenges: IP Rights, Trade Secrets, and Competition
08:50 – Revolutionizing Market Access (AMNOG) through data
09:40 – A "Magna Carta" for Rare Diseases and AI Research
10:30 – Identifying why therapies work (or fail) using broader datasets
11:20 – Closing: Why EHDS requires a "European Village" to succeed
More shows like Faces of Digital Health
View all
Finding Mastery with Dr. Michael Gervais
1,656 Listeners